Literature DB >> 31654317

Galectin-3 Exerts a Pro-differentiating and Pro-myelinating Effect Within a Temporal Window Spanning Precursors and Pre-oligodendrocytes: Insights into the Mechanisms of Action.

Laura Thomas1, Laura Andrea Pasquini2.   

Abstract

Oligodendrocytes (OLG) are the cells resident in the CNS responsible for myelination. OLG undergo a succession of morphological and molecular changes along several maturational stages. Galectin-3 (Gal-3) is a 25- to 35-KDa protein belonging to the family of carbohydrate-binding galectins, which bind to glycoconjugates containing β-galactosides. Gal-3 lacks a specific receptor and its binding is thus rather unspecific, as it depends on the cellular environment and the repertoire of glycomolecules at the time when Gal-3 is present. Our previous work revealed that recombinant Gal-3 (rGal-3)-treated OLG showed accelerated differentiation, evidenced by an increase in the number of mature cells to the detriment of immature ones and accelerated actin cytoskeleton dynamics. These changes were a consequence of rGal-3 influence on Akt, Erk 1/2, and β-catenin signaling pathways. Considering this previous evidence, the aim of this study was to identify the temporal window of rGal-3 action on the OLG lineage to induce OLG maturation by using specific single pulses of rGal-3 over the different maturational stages of OLG, and to unravel its main direct targets promoting OLG differentiation by mass spectrometry analysis. Our results reveal a key temporal window spanning between OPC and pre-OLG states in which rGal-3 action promotes OLG differentiation, and identify several targets for rGal-3 binding including proteins related to the cytoskeleton, signaling pathways, metabolism and intracellular trafficking, among others. These results highlight the relevance of Gal-3 in signaling pathways regulating oligodendroglial differentiation and support a potential therapeutic role for rGal-3 in demyelinating diseases such as multiple sclerosis.

Entities:  

Keywords:  Actin; Galectin-3; Mass spectrometry; Oligodendrocytes; Signal transduction

Year:  2019        PMID: 31654317     DOI: 10.1007/s12035-019-01787-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  6 in total

Review 1.  Thinking outside the box: non-canonical targets in multiple sclerosis.

Authors:  Laura Bierhansl; Hans-Peter Hartung; Orhan Aktas; Tobias Ruck; Michael Roden; Sven G Meuth
Journal:  Nat Rev Drug Discov       Date:  2022-06-06       Impact factor: 112.288

2.  The Diagnostic and Prognostic Value of Plasma Galectin 3 in HFrEF Related to the Etiology of Heart Failure.

Authors:  Qun Lu; Ruo-Chen Zhang; Shu-Ping Chen; Tao Li; Ya Wang; Yan-Bo Xue; Jing Liu; Xiu Han; Yi-Dan Su; Ling Bai; Xiao-Jun Du; Ai-Qun Ma
Journal:  Front Cardiovasc Med       Date:  2021-12-22

Review 3.  Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration.

Authors:  Juan García-Revilla; Antonio Boza-Serrano; Ana M Espinosa-Oliva; Manuel Sarmiento Soto; Tomas Deierborg; Rocío Ruiz; Rocío M de Pablos; Miguel Angel Burguillos; Jose L Venero
Journal:  Cell Death Dis       Date:  2022-07-20       Impact factor: 9.685

4.  Galectin-3 administration drives remyelination after hypoxic-ischemic induced perinatal white matter injury.

Authors:  Qian Wang; Sihao Diao; Han Qiu; Ruiwei Gao; Minjie Wang; Qiufan Chen; Mili Xiao; Zhihua Li; Chao Chen
Journal:  Front Cell Neurosci       Date:  2022-09-20       Impact factor: 6.147

5.  Novel Galectin-3 interactions involved in oligodendroglial differentiation make inroads into therapeutic strategies for demyelinating diseases.

Authors:  Laura Andrea Pasquini
Journal:  Neural Regen Res       Date:  2021-02       Impact factor: 5.135

6.  Galectin-1 and -3 in high amounts inhibit angiogenic properties of human retinal microvascular endothelial cells in vitro.

Authors:  Anna Hillenmayer; Christian M Wertheimer; Arie Geerlof; Kirsten H Eibl; Siegfried Priglinger; Claudia Priglinger; Andreas Ohlmann
Journal:  PLoS One       Date:  2022-03-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.